Hello MSOS members,
I would like to know how your organization mitigates risk with look-alike sound-alike (LASA) medications. Specifically, what are the immediate steps taken at your organization when a product mix-up due to look alike packaging has been identified? I'd like to incorporate an SOP in our organization's LASA policy that outlines a process for physically auditing all patient care and pharmacy areas where the products in question are stored to ensure no additional mix-ups exist, and to segregate the products if necessary. I'm interested in knowing whether other sites have adopted something similar, and if so, what does this process look like. Thank you for your time!
Jennifer Foglio
Adverse Drug Event Coordinator
Cleveland Clinic